CI

At a glance

ClinicalIndex Comparison Record
N/ARecruiting· 20,000 target
Drug / intervention
The study did not involve intervention in the patient's treatment regimenprocedure
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT06591039
NCT06591039N/ARecruitingUpdate OverdueUpdated 21mo ago · Completion was 12mo ago
Enrollment Stalled
Long Recruiting
Update Overdue
CompareCT.gov

A Multicenter Prospective Observational Cohort Study of Breast Cancer Based on a Breast Cancer Medical Record Database in China

Fudan University·observational·Posted Sep 19, 2024·Updated Sep 19, 2024

In Brief

An observational study evaluating The study did not involve intervention in the patient's treatment regimen for Breast Neoplasms. Currently recruiting, targeting 20,000 participants across 1 site.

Signals

Enrollment appears stalled

Detailed Summary

1. To construct a prospective, multi-center breast cancer treatment cohort in China, and analyze the factors affecting breast cancer diagnosis and treatment. 2. To evaluate the diagnosis and treatment and prognosis of breast cancer among patients in different regions and hospitals.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsBreast Neoplasms
CountriesChina
Collaborators--

Timeline

N/ARecruitingOverdue
2023202420252026
First PostedSep 19, 2024
Enrollment StartJul 1, 2022
Primary CompletionJul 1, 2025
Study CompletionDec 31, 2025
TodayJul 1, 2026
Enrollment to primary: 3 yearsPosted 1.8 years ago

Interventions

The study did not involve intervention in the patient's treatment regimenprocedure

This study is based on a prospective database platform to register the occurrence, treatment and prognosis of breast cancer in China, so there is no clear exposure factor. This study was a prospective cohort study, which did not intervene in exposure factors, but only assessed the occurrence, treatment, and prognosis of breast cancer in China.